Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Odds Ratio01:09

Odds Ratio

The odds ratio (OR) is a statistical measure used extensively in epidemiology and research to quantify the strength of association between exposure and outcome across different groups. Unlike relative risk, which compares the probabilities of an event occurring, the odds ratio compares the odds of an event occurring in the exposed group to the odds of it occurring in the unexposed group. The odds, in this context, are calculated as the probability of the event happening divided by the...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Hazard Rate01:11

Hazard Rate

The hazard rate, also known as the hazard function or failure rate, is a statistical measure used to describe the instantaneous rate at which an event occurs, given that the event has not yet happened. From a probabilistic perspective, it represents the likelihood that a subject will experience the event in a very small time interval, conditional on surviving up to the beginning of that interval. In terms of frequency, the hazard rate can be viewed as the ratio of the number of events to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A MAFG~MITF complex drives melanoma phenotype switching and progression.

Nature communications·2026
Same author

Mapping of the hSOX10 Proximal Protein Interactome in Human Melanoma.

Journal of proteome research·2026
Same author

Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer.

Cancer research·2026
Same author

Optogenetic Proximity Labeling Maps Spatially Resolved Mitochondrial Surface Proteomes and a Locally Regulated Ribosome Pool.

bioRxiv : the preprint server for biology·2026
Same author

A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth.

Cancer discovery·2025
Same author

Activating NRF2<sup>E79Q</sup> mutation alters the differentiation of human non-small cell lung cancer.

Cancer gene therapy·2025
Same journal

ZNRF3 and RNF43 are active monomeric E3 ubiquitin ligases that self-associate.

Science signaling·2026
Same journal

Allosteric ligands with distinct properties uncover tissue-specific physiological regulation mediated by free fatty acid receptor 2.

Science signaling·2026
Same journal

Diacylglycerol kinase ζ in B lymphocytes supports CD40-mediated immune synapse formation, mTORC1 signaling, and plasma cell fate.

Science signaling·2026
Same journal

The APC/C adaptor Cdh1 stabilizes STING to potentiate innate immune activation in renal cell carcinoma.

Science signaling·2026
Same journal

Fattening mother's milk with oxytocin.

Science signaling·2026
Same journal

Virion display reveals MD-1 as an endogenous agonist for the orphan receptor GPRC5B.

Science signaling·2026
See all related articles

Related Experiment Video

Updated: Jun 22, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

"Omic" risk assessment.

Michael B Major, Randall T Moon

    Science Signaling
    |May 28, 2009
    PubMed
    Summary
    This summary is machine-generated.

    Effective validation of research "hits" requires integrating data from multiple techniques. This approach moves beyond arbitrary relevance to biologically meaningful target identification in screens.

    Related Experiment Videos

    Last Updated: Jun 22, 2026

    An R-Based Landscape Validation of a Competing Risk Model
    05:37

    An R-Based Landscape Validation of a Competing Risk Model

    Published on: September 16, 2022

    Area of Science:

    • Biochemistry
    • Molecular Biology
    • Genomics

    Background:

    • Large-scale screens generate numerous potential research "hits" that require rigorous validation.
    • Integrating data from diverse experimental techniques is crucial for confirming the significance of these hits.

    Discussion:

    • Discusses validation strategies for both small interfering RNA (siRNA) screens and protein-interaction screens.
    • Highlights the limitations of arbitrary relevance assignment in hit validation.
    • Emphasizes the need for a more biologically meaningful approach to target identification.

    Key Insights:

    • Data integration across different screening methods enhances the reliability of hit validation.
    • Moving beyond simple relevance metrics leads to a deeper biological understanding of identified targets.
    • Biologically meaningful validation is essential for advancing research in genomics and molecular biology.

    Outlook:

    • Future research should focus on developing standardized protocols for data integration in high-throughput screening.
    • This approach will accelerate the discovery of novel therapeutic targets and biomarkers.
    • Enhanced validation methods will improve the translation of screening findings into clinical applications.